Ocugen (OCGN) Competitors $1.34 -0.06 (-4.29%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.36 +0.01 (+1.12%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. MRNA, PFE, SNDX, SDGR, ABCL, TLRY, STOK, AMPH, EVO, and NTLAShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Moderna (MRNA), Pfizer (PFE), Syndax Pharmaceuticals (SNDX), Schrodinger (SDGR), AbCellera Biologics (ABCL), Tilray Brands (TLRY), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Evotec (EVO), and Intellia Therapeutics (NTLA). These companies are all part of the "medical" sector. Ocugen vs. Its Competitors Moderna Pfizer Syndax Pharmaceuticals Schrodinger AbCellera Biologics Tilray Brands Stoke Therapeutics Amphastar Pharmaceuticals Evotec Intellia Therapeutics Moderna (NASDAQ:MRNA) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Do analysts rate MRNA or OCGN? Moderna currently has a consensus target price of $41.81, suggesting a potential upside of 65.66%. Ocugen has a consensus target price of $6.00, suggesting a potential upside of 347.76%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.05Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of MRNA or OCGN? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 11.0% of Moderna shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer MRNA or OCGN? In the previous week, Moderna had 9 more articles in the media than Ocugen. MarketBeat recorded 21 mentions for Moderna and 12 mentions for Ocugen. Moderna's average media sentiment score of 0.75 beat Ocugen's score of 0.59 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 10 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ocugen 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is MRNA or OCGN more profitable? Moderna has a net margin of -94.31% compared to Ocugen's net margin of -1,197.71%. Moderna's return on equity of -25.96% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Ocugen -1,197.71%-255.25%-86.79% Which has more risk and volatility, MRNA or OCGN? Moderna has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.15, suggesting that its stock price is 315% more volatile than the S&P 500. Which has higher earnings and valuation, MRNA or OCGN? Ocugen has lower revenue, but higher earnings than Moderna. Ocugen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.03-$3.56B-$7.53-3.35Ocugen$4.05M96.71-$54.05M-$0.20-6.70 SummaryModerna beats Ocugen on 10 of the 16 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$409.23M$3.15B$5.80B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-6.7020.9180.4326.78Price / Sales96.71448.41534.66123.54Price / CashN/A46.6037.9961.55Price / Book13.409.6615.776.40Net Income-$54.05M-$53.22M$3.30B$271.80M7 Day Performance25.23%3.11%5.37%3.48%1 Month Performance32.67%7.56%8.10%9.89%1 Year Performance20.72%11.15%81.36%28.44% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.6166 of 5 stars$1.34-4.3%$6.00+347.8%+17.5%$409.23M$4.05M-6.7080News CoveragePositive NewsAnalyst ForecastGap UpMRNAModerna4.4715 of 5 stars$23.88+1.6%$41.81+75.1%-62.9%$9.29B$3.24B-3.175,800PFEPfizer4.9846 of 5 stars$23.98+0.5%$28.12+17.3%-19.0%$136.34B$63.63B12.7681,000Positive NewsAnalyst UpgradeSNDXSyndax Pharmaceuticals3.7533 of 5 stars$15.84+1.9%$39.22+147.6%-20.7%$1.36B$77.93M-4.07110Analyst ForecastSDGRSchrodinger3.4947 of 5 stars$18.46-0.6%$27.83+50.8%-6.7%$1.36B$207.54M-7.44790Positive NewsABCLAbCellera Biologics3.1188 of 5 stars$4.35-2.7%$8.00+83.9%+64.6%$1.30B$28.83M-7.91500TLRYTilray Brands2.8597 of 5 stars$1.18+5.4%$1.94+64.2%-32.0%$1.30B$821.31M-0.512,842STOKStoke Therapeutics3.8157 of 5 stars$23.40-0.3%$25.57+9.3%+51.3%$1.28B$36.56M27.53100Positive NewsAMPHAmphastar Pharmaceuticals4.0501 of 5 stars$27.27-2.8%$31.60+15.9%-44.8%$1.27B$731.97M10.212,028Positive NewsEVOEvotec1.6193 of 5 stars$3.50+0.9%$5.40+54.3%+0.0%$1.24B$862.40M0.004,827News CoverageNTLAIntellia Therapeutics4.46 of 5 stars$11.57+1.3%$27.11+134.3%-32.0%$1.24B$57.88M-2.47600Trending NewsAnalyst ForecastOptions Volume Related Companies and Tools Related Companies Moderna Alternatives Pfizer Alternatives Syndax Pharmaceuticals Alternatives Schrodinger Alternatives AbCellera Biologics Alternatives Tilray Brands Alternatives Stoke Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Evotec Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
